BioMérieux is a worldwide leading provider of diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and reduce risk of hospital infections spreading.
BioMérieux EpiSeq is an innovative next-generation sequencing (NGS) service dedicated to the epidemiological monitoring and control of healthcare-associated infections. These can include Methicillin resistant Stapylococcus Aureus (MRSA), Pneumococcus infections (to include Pneumonia and Meningitis) and Urinary tract infections (through catheter usage in hospitals).
By giving hospitals an improved understanding of the genetic markers of virulence and resistance, the service can help them understand how bacteria are transmitted, while enabling better containment of an epidemic, limiting the spread of infectious agents and improving surveillance approaches.
Signed by bioMérieux and Illumina in November 2014, the bioMérieux EpiSeq service aims to bring together the companies’ respective leadership positions in microbiology and NGS to jointly develop applications for microbiology sequencing.